Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Blanca Torrejón

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

B. Torrejón1, M. Pedregal Trujillo2, A. Santos1, J. Rubio2, M. Luque1, M. Sanz1, C. Carames2, S. Zazo1, J. Madoz-Gurpide1, F. Rojo1, J. Garcia Foncillas2, C. Ion1

Author affiliations

  • 1 Molecular Biology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 2 Clinical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
More

Resources

Abstract 5912

Background

SET deregulation is an alteration that determines poor outcome in metastatic colorectal cancer (CRC) patients promoting cell growth and decreasing sensitivity to standard chemotherapeutic agents such as oxaliplatin and 5-fluorouracil. Moreover, this alteration represents a key event to inhibit the tumor suppressor PP2A in metastatic CRC. However, the role of SET in CRC progression and its potential clinical impact in early-stage CRC patients still remain to be investigated.

Methods

In this work, we studied the biological effects of SET on migration using wound-healing and transwell migration assays, and cell invasion ability was determined by colony-forming assays after SET silencing or overexpression. Moreover, we analyzed SET expression by immunostaining in a cohort of 231 CRC patients without metastatic disease at diagnosis. We also quantified the expression of the negative SET regulator miR-199b in a set of CRC patient samples.

Results

We observed that SET deregulation promotes cell migration and markedly affects invasion ability of CRC cells. At the clinical level, SET overexpression was detected in 14.7% of cases. We found this alteration associated with worse ECOG performance status, and with relapse in the subgroup of stage II CRC patients. Moreover, SET overexpression determined significantly shorter overall survival and time to metastasis. Interestingly, its prognostic value was particularly evident in patients older than 70 years. We also identified miR-199b downregulation as a molecular mechanism to deregulate SET in CRC patients with localized disease.

Conclusions

Of importance, our results indicate that SET could serve to anticipate undesirable relapses in stage II CRC patients and define a subgroup of early stage CRC patients that could benefit by the use of SET antagonists or PP2A-activating drugs such as FTY720 in anticancer protocols.

Clinical trial identification

Legal entity responsible for the study

Fundación Jiménez Díaz.

Funding

This work was supported by PI15/00934 and PI16/01468 grants from “Instituto de Salud Carlos III FEDER”. BT is supported by Fundación Conchita Rábago de Jiménez Díaz.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings